STOPCAP M0, bisphosphonates, systematic review and aggregate data meta-analysis
Addition of bisphosphonates to standard of care in men with localised, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
Does the addition of bisphosphonates improve survival for men with prostate cancer that has not spread?
What was this study about?
A systematic review and aggregate data meta-analyses was carried out bringing together trials that looked at whether adding bisphosphonates to standard of care, improved survival in men with localised prostate cancer. Analyses focused on the bisphosphonate called zoledronic acid as this is what is currently being used in practice.
What difference did this study make?
The addition of zoledronic acid to standard of care showed no improvement in survival in men whose disease has not spread (non-metastatic).
Vale CL, Burdett S, Rydzewska LH, Albiges L, Clarke NW, Fisher D, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncology. 2016;17(2):243-56
Details of this and other reviews in metastatic, hormone-sensitive prostate cancer are available here www.stopcapm1.org
Type of study
Who funded the study?
UK Medical Research Council
When did it take place?
This study was fully published in 2016 and brought together the results of trials that were carried out between 1994 and 2013.
Where did it take place?
This study was done at the MRC Clinical Trials Unit at UCL but brings together the results of trials from all over the world.
Who was included?
This study brought together 4 trials (4079 patients) that studied the addition of bisphosphonates to standard of care in men with hormone-sensitive prostate cancer that had not spread.